Skip to main content
Transcenta Holding Limited logo

Transcenta Holding Limited — Investor Relations & Filings

Ticker · 6628 ISIN · KYG9005B1041 HKEX Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2022-05-12 AGM Information
Country HK Hong Kong
Listing HKEX 6628

About Transcenta Holding Limited

http://www.transcenta.com

Transcenta Holding Limited is a clinical-stage global biotherapeutics company specializing in the discovery, research, development, and manufacturing of differentiated antibody-based therapeutics. The company operates a fully integrated platform, utilizing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate candidate leads. Its robust pipeline includes therapeutic antibody molecules targeting oncology and selected non-oncology indications, such as bone and kidney disorders. The company employs advanced bioprocessing technologies, including perfusion-based continuous bioprocessing, to accelerate process development and reduce manufacturing costs.

Recent filings

Filing Released Lang Actions
PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a circular from Transcenta Holding Limited regarding the Annual General Meeting (AGM) scheduled for June 10, 2022. It includes details about the proposed re-election of directors, granting of general mandates to repurchase and issue shares, and the notice of the AGM itself. The content is typical of materials sent to shareholders ahead of an AGM to inform them of the agenda and voting procedures. It also includes proxy form instructions and special arrangements for the meeting, such as COVID-19 precautions. This type of document is classified as AGM Information (AGM-R) because it is the presentation and materials shared for the AGM, not the results of the meeting or a report publication announcement. The document length and detail confirm it is not a brief announcement but a full circular for the AGM.
2022-05-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return filed to the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Transcenta Holding Limited. It details movements in authorized and issued share capital, share options, and confirmations related to securities issued during the month ended 30 April 2022. The document is structured as a regulatory return with detailed share capital and securities movement data, typical of regulatory filings required by the exchange. It is not a full financial report, earnings release, or management discussion. It is also not an announcement of a report publication but a formal regulatory submission. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory compliance documents that do not fit other specific categories.
2022-05-06 English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON PRESENTATION OF CLINICAL TRIAL DATA OF TST001 AND MSB0254 AT 2022 ASCO ANNUAL MEETING
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Transcenta Holding Limited regarding a business update on the presentation of clinical trial data at the 2022 ASCO Annual Meeting. It provides details about the abstracts accepted, the nature of the clinical trials, and the presentation schedule. There are no financial statements, regulatory certifications, or detailed financial data. The document is an announcement of a business update related to clinical trial presentations rather than a financial report or regulatory filing. It is not an Annual Report, Interim Report, Earnings Release, or any other financial filing. Given the content and context, this fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-04-29 English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON THE FIRST PATIENT DOSED IN CHINA STUDY OF ANTI-SCLEROSTIN MONOCLONAL ANTIBODY TST002 FOR THE TREATMENT OF OSTEOPOROSIS
Regulatory Filings Classification · 95% confidence The document is a voluntary business update announcement by Transcenta Holding Limited regarding the dosing of the first patient in a Phase I clinical study for a drug candidate. It provides information about the clinical trial, drug background, and company activities related to drug development. There are no financial statements, regulatory certifications, voting results, or detailed financial data. The document is an announcement of a business update rather than a formal financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation or a call transcript. Given the nature of the content as a voluntary business update announcement, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2022-04-28 English
NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS
Report Publication Announcement Classification · 100% confidence The document is a notification to shareholders about the publication of the company's annual report for the year ended 31 December 2021 on the company's website. It includes instructions on how to access the report online and how to request a printed copy. The document itself does not contain the annual report or any financial data but serves as an announcement of the report's availability. The document length is 6333 characters, which is relatively short and consistent with an announcement rather than the full report. According to the 'MENU VS MEAL' rule, this type of document should be classified as a Report Publication Announcement (RPA) rather than the Annual Report (10-K).
2022-04-27 English
2021 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled '2021 Annual Report' and contains detailed sections typical of an annual report, including CEO's statement, financial highlights, management discussion and analysis, report of directors, corporate governance report, independent auditor's report, consolidated financial statements, and notes. The content covers the full fiscal year ended December 31, 2021, and includes comprehensive financial data and analysis. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-04-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.